206 studies found for:    HLA-C
Show Display Options
Rank Status Study
1 Unknown  Maternal KIR and Fetal HLA-C Genes in Recurrent Miscarriages
Condition: Recurrent Miscarriages
Intervention:
2 Completed
Has Results
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
Conditions: Leukemia;   Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin;   Drug: fludarabine phosphate;   Drug: thiotepa;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
3 Unknown  bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients
Condition: Cutaneous Warts
Interventions: Drug: bLAC;   Drug: Placebo
4 Unknown  Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells
Condition: Myeloblastic Leukemia
Intervention: Biological: NK cells
5 Completed Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection
Condition: Kidney Transplantation
Intervention: Biological: C1 Esterase Inhibitor
6 Completed A Phase I Safety and Immunogenicity Trial of HIV-1 gp120 C4-V3 Hybrid Polyvalent Peptide Immunogen Mixed in Mineral Oil Containing Mannose Mono-Oleate (IFA)
Condition: HIV Infections
Intervention: Biological: HIV-1 C4-V3 Polyvalent Peptide Vaccine
7 Terminated Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%
Condition: Kidney Failure, Chronic
Intervention: Biological: Immune Globulin Intravenous (Human), 10%
8 Recruiting A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma
Condition: Synovial Sarcoma
Intervention: Biological: NY-ESO-1 T Cells
9 Terminated
Has Results
Vaccine Treatment of Kidney Cancer
Condition: Kidney Cancer
Interventions: Drug: 117-126:Fibroblast growth factor 5 (FGF-5);   Drug: Fibroblast growth factor 5 (FGF-5):172-176/217-220;   Other: IL-2
10 Completed
Has Results
Chloroquine for Reducing Immune Activation in HIV- Infected Individuals
Condition: HIV Infections
Interventions: Drug: Chloroquine;   Drug: Placebo
11 Recruiting T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Conditions: Acute Lymphoblastic Leukemia;   Non Hodgkins Lymphoma;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelogenous Leukemia;   Hemophagocytic Lymphohistiocytosis (HLH);   Familial Hemophagocytic Lymphohistiocytosis (FLH);   Viral-associated Hemophagocytic Syndrome (VAHS);   X-linked Lymphoproliferative Disease (XLP)
Interventions: Drug: Ara-C;   Drug: Cyclophosphamide;   Biological: Campath-1H;   Radiation: Total Body Irradiation;   Procedure: Stem Cell Infusion
12 Recruiting Treatment of Sickle Cell Anemia With Stem Cell Transplant
Conditions: Sickle Cell Anemia;   Sickle Cell-hemoglobin C Disease;   Sickle Cell-β0-thalassemia
Interventions: Drug: Fludarabine;   Drug: Cytarabine;   Device: Cellular Infusions;   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Bortezomib;   Drug: Rituximab;   Procedure: Plasmapheresis
13 Completed
Has Results
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: Reyataz + Norvir + Truvada;   Drug: Reyataz + Epzicom
14 Recruiting HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome
Condition: Atrophic Glossitis, Burning Mouth Syndrome
Intervention: Dietary Supplement: Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic
15 Completed Risk-adapted Therapy for Adult Acute Myeloid Leukemia.
Condition: Leukemia, Myelocytic, Acute
Interventions: Drug: Ara-C;   Other: Autologous transplantation;   Other: Allogeneic HLA-identical sibling transplantation;   Other: CD34+ selection
16 Terminated Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides
Condition: Melanoma
Interventions: Biological: Immunological peptides and immunological adjuvants;   Biological: HLA-A2 peptides;   Biological: Montanide ISA51;   Biological: IMP321
17 Unknown  Racial Difference in HCV/Host Interactions
Condition: Hepatitis C
Intervention:
18 Unknown  Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma
Condition: Mantle-Cell Lymphoma
Interventions: Drug: Immunochemotherapy;   Drug: High-dose BEAM plus autologous SCT;   Other: HLA-identical allogenic SCT
19 Completed Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
Conditions: Graft Versus Host Disease;   Leukemia;   Myelodysplastic Syndromes
Interventions: Biological: Filgrastim;   Drug: Cladribine;   Drug: Cyclosporine;   Drug: Cytarabine (Ara-C);   Drug: Fludarabine Phosphate;   Drug: Idarubicin;   Drug: Methylprednisolone;   Procedure: Peripheral Blood Stem Cell Transplantation
20 Unknown  Identification of Hepatitis C Virus (HCV) Specific T Cells
Condition: Hepatitis C
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years